PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS)

Smith, E.M.D.; Aggarwal, A.; Ainsworth, J.; Al-Abadi, E.; Avcin, T.; Bortey, L.; Burnham, J.; Ciurtin, C.; Hedrich, C.M.; Kamphuis, S.; Lambert, L.; Levy, D.M.; Lewandowski, L.; Maxwell, N.; Morand, E.; Ozen, S.; Pain, C.E.; Ravelli, A.; Saad Magalhaes, C.; Pilkington, C.; Schonenberg-Meinema, D.; Scott, C.; Tullus, K.; Beresford, M.W.; Goilav, B.; Marks, S.; Oni, L.

doi:10.1016/j.clim.2023.109296

PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS)

Atıf İçin Kopyala

Smith E., Aggarwal A., Ainsworth J., Al-Abadi E., Avcin T., Bortey L., ...Daha Fazla

Clinical Immunology, cilt.250, 2023 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 250
Basım Tarihi: 2023
Doi Numarası: 10.1016/j.clim.2023.109296
Dergi Adı: Clinical Immunology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
Anahtar Kelimeler: Childhood-SLE, cLLDAS, cSLE, Low disease activity, T2T, Treat-to-target
Hacettepe Üniversitesi Adresli: Evet

Özet

Objective: To achieve a consensus-based definition of Low Disease Activity (LDA) for use in cSLE trials. Methods: The International cSLE T2T Task Force, comprising of paediatric rheumatologists/nephrologists, and adult rheumatologists undertook a series of Delphi surveys/consensus meetings to discuss, refine, and vote upon cSLE LDA criteria. Results: The Task Force agreed that LDA should be based upon the adult-SLE Lupus Low Disease Activity State definition (LLDAS), with modifications to make it applicable to cSLE (cLLDAS). They agreed upon five cLLDAS criteria: (1) SLE Disease Activity Index (SLEDAI)-2 K ≤4, with no activity in major organ systems; (2) no new features of lupus disease activity compared with the last assessment; (3) Physician Global Assessment score of ≤1 (0–3 scale); (4) prednisolone dose of ≤0.15 mg/kg/day, 7.5 mg/day/maximum; while on (5) stable antimalarials, immunosuppressives, and biologics. Conclusions: A cSLE-appropriate definition of cLLDAS has been generated, maintaining alignment with the adult-SLE definition to promote life-course research.